期刊名称：CANCER BIOLOGY & MEDICINE
|
ISSN： | 2095-3941
|
|
出版频率： | Quarterly
|
|
出版社： | CHINA ANTI-CANCER ASSOC, TIANJIN MEDICAL UNIV, CANCER INST & HOSPITAL TI-YUAN-BEI, HUANHU XI LU, HEXIQU, TIANJIN, PEOPLES R CHINA, 300060
|
|
出版社网址： | http://www.caca.org.cn/
|
|
期刊网址： | http://www.cancerbiomed.org/index.php/cocr/
|
|
影响因子： | 4.248 |
| 主题范畴： | ONCOLOGY; MEDICINE, RESEARCH & EXPERIMENTAL; China Journals |
| 变更情况： | |
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Cancer Biology & Medicine is a peer-reviewed open-access journal published by the Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:
● Cancer genetics
● Cancer and stem cell biology
● Molecular and clinical immunology
● Cancer prevention and epidemiology
● Cancer biomarkers
● Radiation oncology
● Oncology clinical trials
● Mechanisms of drug sensitivity and resistance
● Targeted therapy and immunotherapy
● Multidisciplinary treatment and personalized medicine
Author Benefits
● Easy submission via online system
● Efficient and professional peer review
● Rapid pre-print online publication
● No charge for publication and open access
● International visibility-All full texts are free in PubMed Central
期刊名称
中文： 癌症生物学与医学
英文： Cancer Biology & Medicine
Cancer Biology & Medicine (《癌症生物学与医学》)是由中国科协主管，中国抗癌协会主办，天津医科大学肿瘤医院（国家肿瘤临床研究中心）出版的英文期刊，以促进肿瘤学基础与临床研究的转化为办刊宗旨。中国抗癌协会理事长、中国工程院院士郝希山教授担任主编。
Cancer Biology & Medicine遵循国际办刊标准，严格审查来稿，坚决抵制学术不端；实行严谨规范的同行评议制度，重点刊登有较高学术水平与应用价值的论文。经过十余年的发展，该刊已成为一本国际化的专业刊物，编委会由来自29个国家与地区的优秀学者组成，发文作者来自30多个国家，读者群覆盖全球。
作为国内自主创办与出版的英文期刊，Cancer Biology & Medicine在学术质量与国际影响力提升方面取得可喜成绩，被国际权威检索系统PubMed与《科学引文索引》(Science Citation Index Expanded, SCIE)收录，荣获“2016年中国最具国际影响力学术期刊”等荣誉。作为肿瘤学科学术共同体的一部分，该刊将在推动肿瘤防控及为我国肿瘤学科研人员争取国际话语权等方面发挥积极作用。
Instructions to Authors
ABOUT THE JOURNAL
Cancer Biology & Medicine is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Quarterly published, the journal provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:
- Cancer genetics
- Cancer and stem cell biology
- Molecular and clinical immunology
- Cancer prevention and epidemiology
- Cancer biomarkers
- Radiation oncology
- Oncology clinical trials
- Mechanisms of drug sensitivity and resistance
- Targeted therapy and immunology
- Multidisciplinary treatment and personalized medicine
The journal adheres to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, issued by the International Committee for Medical Journal Editors (ICMJE) and the guidelines of Committee on Publication Ethics (COPE).
MISSION
Cancer Biology & Medicine dedicates to present cutting-edge and high quality articles on basic, clinical, and translational cancer research, in an effort to keep cancer researchers and clinicians with current knowledge of novel findings and recent advances in oncology throughout the world.
AUDIENCE
Cancer Biology & Medicine endeavors to appeal a diverse audience engaged in cancer research and subspecialties in clinical oncology. Readers may include, but not limited to, investigators, physicians, surgeons and nurses in cancer research areas, medical students, and other relevant health care professionals.
CONTENT CATEGORIES
Original Article, Editorial, Review, Minireview, Letter to the Editor, Clinical Guideline, Meeting Report, Case Report, and UICC-China Spoke News.
INDEXING INFORMATION
Cancer Biology & Medicine is indexed in PubMed/PubMed Central, BIOSIS Previews, EMBASE, SCOPUS, EBSCO, DOAJ, and Chemical Abstracts.
EDITORIAL POLICIES
Authorship and Contributorship
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. The corresponding author is required to ensure that authors are appropriately listed and provide information on the specific contributions each author has made to the article. The manuscript’s content and its submission for publication should be approved by all authors. Contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please be aware that all communications during the submission and publishing process will be sent to the corresponding author.
Ethics Involving Humans and Animals
Experiments on human subjects should follow the Helsinki Declaration (as revised in 2013) and should be approved by an ethics committee. Written informed consents should be obtained from all participants. Concerning privacy and/or security of personal information, informed consents, permissions, and releases must be obtained in regard to case details, personal information, and/or images used. Animal experiments should abide by the institutional and national guide for the care and use of laboratory animals. The above information should be stated in the paper.
Conflict of Interest
Conflict of interest exists when an author (or the author’s institution), reviewer, or editor has any financial or personal relationships that may inappropriately influence (bias) his or her actions. Cancer Biology & Medicine requires all authors to disclose any relationship that might result in an actual, potential, or perceived conflict of interest about the manuscript submitted for review. Reviewers and editors should also disclose all relationships that may undermine the credibility of the publication process.
Exclusive Submission
Manuscripts are considered for review only if no part of the work has been previously published in print or electronically. Previous publication of an abstract in the proceedings of meetings does not preclude whole manuscript submission for publication, but full disclosure should be made. At submission, the corresponding author is responsible to attest that the manuscript, in whole or in part, is not under consideration, in press, or published in any other publication or electronic medium.
Copyright and Permissions
If a manuscript includes copyrighted materials of others, authors must obtain written permission from the copyright owners and indicate the sources in the article. The written permission should be simultaneously submitted with the manuscript.
Upon acceptance of a manuscript, authors are invited to transfer copyright to facilitate the dissemination of information to a maximum extent. Cancer Biology & Medicine will not publish a manuscript until the Copyright Transfer Form with all authors’ signatures is returned. After copyright transfer, authors (or their employees and institutions) reserve the following rights.
- Reproducing the manuscript in whole or in part for teaching, lecture presentation, and communication in conferences.
- Including parts of the manuscript in subsequent articles or books, with acknowledgement of its original publication in Cancer Biology & Medicine.
- Posting the accepted version of the manuscript (revised according to peer reviewers’ opinions) on personal or institutional website, with a link to the final published version on the website of Cancer Biology & Medicine.
- Using the manuscript fully or in part in a doctoral thesis or dissertation.
For third parties who intend to use materials copyrighted in Cancer Biology & Medicine, please visit the website of Copyright Clearance Certer to apply for permission, here is the link http://www.copyright.com/search.do?operation=detail&item=346421242&detailType=basic .
Checking for Scientific Misconduct
Cancer Biology & Medicine has an obligation to ensure that its published articles are accurate and adheres to the highest ethical standard. Editors check all submissions using CrossCheck. In the cases of plagiarism, redundant or duplicate publication, the journal will send a letter of reprimand to the authors’ institution, publish a notice of misconduct and formally retract the published manuscript. The journal will remove further association with the involved authors and institutions.
Peer Review
After initial review by the editor or sometimes by an editorial board member, manuscripts without sufficient priority for publication will be editorially rejected within 7 days. Those qualifying for peer review will be sent to at least two expert reviewers for unbiased, independent and critical assessment. Peer reviewers’ identities are kept confidential, but authors’ information will be provided to the reviewers. The editors endeavor to reach decisions on these papers within four weeks from the original submission date. We allow authors two weeks for general revision and one month for major revision. Accepted papers will be published in print within four months of acceptance.
Embargo Policy
Scientific information in a manuscript which is under consideration or in press in Cancer Biology & Medicine may not be discussed with the media before publication. Preliminary reporting to public media, governmental agencies, or manufacturers should not jeopardize publication, and should be discussed with and approved by the editor in advance.
Responses to Scientific Misconduct
Cancer Biology & Medicine has an obligation to ensure that its published research is accurate and adheres to the highest ethical standard. In the cases of falsification, plagiarism, redundant or duplicate publication, the journal will send a letter of reprimand to the authors’ institution, publish a notice of misconduct and formally retract the published manuscript. The journal will remove further association with the involved authors and institutions.
Advance Online Publication
All accepted articles will be published online (www.cancerbiomed.org) before print as the final version after revision and editing, with a unique digital object identifier (DOI).
Open Access
All accepted articles will be archived as open access documents on www.cancerbiomed.org in their final published form, with no charge for authors.
MANUSCRIPT SUBMISSION
Presubmission Inquiries
Authors interested in getting rapid feedback on whether a manuscript is likely to be published in Cancer Biology & Medicine are encouraged to send inquiries by e-mail (editor@cancerbiomed.org). The inquiries should at least include an abstract and significant figures and tables. A paper that is invited for submission after a presubmission inquiry is still subject to editorial review to assess for external peer review.
Online Submission
We encourage authors to submit manuscripts via our online submission and tracking system: http://mc03.manuscriptcentral.com/cbm. Please avoid sending your manuscript by e-mail attachment.
Questions and required documents in submission process:
● Manuscript type
● Manuscript title
● Running title with no more than 10 words
● Full names including first and middle names of all authorsshould be provided, the affiliation of everyone, as well as thee-mail address of corresponding author(s) should be also included
● Abstract is the sketch of core content of the whole paper,particularly, it should offer the purpose of the study, themethods used, and results and conclusions in an original article.References could not appear in abstract, also, abbreviations andacronyms should be avoided
● At least 5 keywords should be provided on the maininformation of the paper
● A cover letter should be uploaded along with the paper (seemore details below)
● The approval from an ethics committee should be offered whenthe paper, especially original article, refers to clinical trials
● Upload PDFs or other files for Supplementary Data (if applicable)
● Answers to some other questions such as listing the reviewers recommended by author(s) and so on.
Our online submission system will prompt you to upload the components of your manuscript (cover letter, text, figures, supplemental data, etc.) as separate files. Upon completion of this step, the website will build a composite PDF file of your entire manuscript. Authors are responsible to check the format of manuscript and quality of figures in the converted PDF file and approve the submission.
Cover Letter
Each submission must be accompanied by a cover letter, which should contain the following information:
- The title and a brief summary of the significant findings or points of the manuscript.
- A statement of exclusive submission and no plagiarism or other misconducts.
- A statement that the manuscript has been read and approved for submission by all the authors.
- The name, address, and telephone number of the corresponding author.
- Suggestions for appropriate reviewers and reviewer exclusions.
Status Inquiries
Authors can check the status of the submitted manuscripts at any time in the review process by accessing the system with their account and password. Please feel free to send status queries to the editor@cancerbiomed.org.
Revision Submission
The revised version of manuscript should be submitted within two months after authors receive the reviewers comments. Please contact the editor if extra time is needed for revision. The journal generally allows only one round of revision. Except for the revisions, authors should upload a point-by-point response to the reviewers’ comments. Please do not upload revised manuscripts as new submissions.
MANUSCRIPT FORMATS
Original Article
Original Articles report significant new findings or important clinical experience in cancer area, which have valuable implications.
● 300-word abstract
● 6,000 words of text
● 50 references or more
● 8 figures and/or tables in maximum
● Results and Discussion must not be combined.
● Additional display items may be published as supplementary information.
Editorial
Editorials are usually invited, commenting on the leading-edge discoveries in cancer research and significant advances on cancer diagnosis and treatment.
● 3,000 words of text
● 10 references or more
● 3 figures and/or tables in maximum
Perspective
Perspectives present a viewpoint on an important area of research and are written only at the invitation of the Editorial Board. Perspectives focus on a specific field or subfield within a larger discipline and discuss current advances and future directions, sometimes with personal insights.
● 3,500 words of text
● 10 references or more
● 3 figures and/or tables in maximum
Review
Reviews discuss recent progress on topics of broad interest to cancer researchers or cancer care professionals. Solicited reviews will also be sent out for peer review.
● 250-word abstract
● 7,000 words of text
● 75 references or more
● 7 figures and/or tables in maximum
Minireview
Minireviews are shorter reviews, usually based on recently published original studies. Solicited minireviews will also be sent out for peer review.
● 200-word abstract
● 4,000 words of text
● 50 references or more
● 5 figures and/or tables in maximum
Letter to the Editor
Readers are encouraged to comment on articles published in Cancer Biology & Medicine, via Letters to the Editor. Letters to the editor will not undergo peer review.
● A Letter should clearly indicate the original source.
● Response to a Letter should reference the Letter in the first paragraphs and its title should include the Letter title.
● 500 words of text
● 5 references or more
Case Report
Case Reports introduce new, rare or typical cancer cases. The features, diagnosis or treatment of these cases should have valuable implications and provide practical information for clinicians.
● 100-word abstract
● 1,000 words of text
● 10 references or more
● 7 figures and/or tables maximum
● Including 3 sections, namely Introduction, Case Report, andDiscussion
Meeting Report
Meeting Report presents essence of important cancer conferences or symposia all over the world, such manuscripts should contain novel information and insightful views of the meeting and should be submitted within three months of the meeting date.
● 100-word abstract
● 3,000 words of text
● 10 references or more
● 5 figures and/or tables maximum
Practice Guideline
Practice Guidelines introduce consensuses or clinical guidelines produced by international authoritative groups or societies about cancer.
MANUSCRIPT PREPARATION
Authors should prepare their manuscripts according to the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals established by the ICMJE (http://www.icmje.org) (http://www.icmje.org). The editors have the right to return manuscripts that are not in accordance with the journal’s policies and format requirements. Manuscripts must be written in concise and fluent English. It is suggested that authors have their manuscript reviewed by colleagues and/or by professional English language editing services before submission.
The manuscript of observational and experimental articles should include title page, abstract, introduction, materials and methods, results, discussion, acknowledgements, conflict of interest statement, references, figures, tables, and supplementary information. All pages of the manuscript should be numbered consecutively, beginning with the title page.
Title Page
Title Key information should be included in the title, which enables electronic retrieval of the article both sensitive and specific. The title should not contain any abbreviations except for commonly used gene or protein acronyms. The total length of the title should not exceed 20 words.
Authors and AffiliationsMultiple first-authorships are acceptable and should be indicated. Multiple senior authors are also acceptable but only one should be designated as corresponding person for timely communication between authors and the journal. The name, mailing address, telephone and fax numbers, and e-mail address of the corresponding author should be indicated clearly. Numbers in superscript should be used to indicate the department, institution, city with postal code and country, for each author.
Author ContributionCancer Biology & Medicine requires a statement specifying the contributions of every author on the title page.
Source(s) of SupportAny support in the form of grants, equipment, drugs, or all of these should be claimed.
Running Title A running title of no more than 10 words is required.
Abstract
This should be a single paragraph of about 250 words, accurately reflecting the content of the article. Abbreviations and reference citation should be avoided in the abstract. The abstract should describe all key novel findings of the study. Structured abstracts (Objective, Methods, Results, and Conclusion) are preferred for original research articles. For articles on clinical trials, items identified by the CONSORT group should be provided and the trial registration number should be listed at the end of the abstract.
Keywords
Authors should list keywords (up to five) which reflect the key information of the article. Medical Subject Headings (MeSH) should be used as a guide (http://www.nlm.nih.gov/mesh/meshhome.html).
Introduction
The Introduction section should provide the necessary background and the specific purpose of the research. Cite references to the most pertinent articles and avoid including data or conclusion of the study being reported.
Materials and Methods
Information about materials and methods should be brief and adequate so that all procedures can be repeated by others. Methods that have been well described in previous publications should be merely cited with appropriate references. Only new and substantially modified methods need detailed explanation. The generic name (s), dose (s), and administration route (s) of all drugs and chemicals should be precisely identified.
Describe statistical methods with enough details. Provide references for the statistical methods when possible and explain whether their data conform to the assumptions of the tests. The computer software used should be specified. Authors should be aware that statistical analysis and presentation is an essential part to review for all referees.
Manuscripts involving humans and animals must include a statement in this section that the research has been reviewed and approved by institutional ethical committee before conduction of research. For manuscripts involving human subjects, a statement that the informed consent was obtained from each subject is required.
Results
The results should be presented in logical sequence in the text, tables, and figures, accurately describing important findings of the study. Concisely summarize the data presented in tables and figures, avoiding excessive explanations.
Discussion
Accurately interpret the new and important findings of the study and discuss the results in a broader context. Avoid repeating materials already showed in the Introduction or the Results section. Pertinent data in previous publications should be appropriately discussed and cited. Discuss the limitations and implications of the study. Avoid drawing conclusions without adequate support by the data.
Conflict of Interest
In this section, whether there is a Conflict of Interest should be stated. Authors must disclose the details of all conflicts if there are any.
Acknowledgements
Contributions of non-authors should be acknowledged. The corresponding author is responsible to obtain the written permission from those mentioned in this section. The funding sources (if any) should be listed, with grant name and number.
References
Cancer Biology & Medicine requires the citation of original research articles wherever appropriate. Number the references in the order of their first mention. References should include only articles that are published or in press. Avoid citing abstracts, personal communication, or retracted articles. Authors are responsible for the accuracy of references and should ensure that the pertinent literatures are appropriately cited and comprehensively discussed. Please use the following style for references:
Article in a Journal: Ulivi P, Delmonte A, Chiadini E, CalistriD, Papi M, Mariotti M, et al. Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection? Int J Mol Sci. 2014; 16: 747-57.
Article in a book: Gradishar W. Male breast cancer. In: Harris J, Lippman M, Morrow M, Osborne C, eds. Diseases of the breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins. 2000: 661-7.
An entire book: Bruce A. Chabner, Dan L. Longo. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia: Lippincott Williams & Wilkins. 2006.
Online first articles: Gregg W. Stone, Akiko Maehara, Bernhard Witzenbichler, et al. Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized Trial. JAMA. Published online first: March 25, 2012. DOI: 10.1001/jama.2012.421
Tables
Type tables on separate sheets and number them consecutively in Arabic numerals according to the order of their first mention in the text. Tables should be self-explanatory and include a brief descriptive title above. Column headings should be concise, with units of measurement in parentheses. Explain all abbreviations in footnotes and use the following symbols, in sequence: †, ‡, §, ¶, etc. *, **, ***, etc. should be reserved for P values.
Figures
Figures should be labeled in consecutive Arabic numerals and presented in the order they are mentioned in the text. If reuse of a figure in previously publications is necessary, the author must provide the written permission from the copyright holder and indicate the original source in the legend.
The figures should be submitted as separate files, in TIF, EPS, JPEG, or GIF formats and should be sized at 127×173 mm (5×7 inches). High resolution is preferred. At least 300 dpi for color figures and 1,000 dpi for line figures are required. Photomicrographs should have internal scale markers. Symbols, arrows, or letters used in photomicrographs should contrast with the background.
Figure legends should be concise and comprehensive and be listed in a separate page. Ensure that legends and figures match up correctly. Indicate stains and magnifications and clearly explain symbols, arrows, abbreviations, and letters used in the legends.
Supplementary Information
Supplementary data should enhance, but not be essential to, a reader's understanding of the paper. Without them, the article also must be complete and clear. Supplementary data will also be sent out for peer review as equal in quality as the main paper.
Supplementary files may consist of the following contents:
● Figures and/or tables
● Materials and methods mentioned in the main paper should be described in details
● Database information
● Electronic multimedia documents (e.g., videos, audios)
Restrictions on number and size of files:
● The number of supplementary files per article should not exceed 8.
● The file size should not exceed 10 MB.
Submit supplementary information as a separate file through thesubmission system.
Each supplementary item/file must be referenced at least once in the paper. The form of tables or figures in supplementary items should follow the related requirements used for the manuscript, for instance, “Figure S1” stands for supplementary Figure 1, or“Table S3” stands for supplementary Table 3.
PROOFS
Authors whose articles are accepted will receive an e-mail with their proof before publication. Authors should check the accuracy and the layout of the text, tables and figures. The PDF should be clearly annotated for necessary corrections and then returned via e-mail to editor@cancerbiomed.org by the date indicated. Major alterations which may delay the publication are not encouraged.
CHARGES
Sponsored by CACA, Cancer Biology & Medicine emphasizes on rapidly publishing leading-edge information on cancer and promoting its dissemination. No fees will be charged for color figures, online/print publication, or Open Access.
OFFPRINTS
Offprint order forms will be sent with the proofs. Authors who request offprints should complete and return the forms to the editorial office before the journal is printed. Late orders submitted after the print publication may be subject to an increased price.
CONTACT INFORMATION
Mainland China
- Tianjin Medical University Cancer Institute and Hospital,
- Huan-hu-xi Road, He-xi District, Tianjin 300060, China
- Tel: 8622-23522919
- Fax: 8622-23522919
- E-mail: editor@cancerbiomed.org
- Website: www.cancerbiomed.org
North America
- Kai Fu, M.D., Ph.D., Associate Editor-in-Chief
- Department of Pathology and Microbiology
- University of Nebraska Medical Center
- 983135 Nebraska Medical Center, Omaha, NE 68198-3135,USA
- Tel: 1-402-559-7526 or 1-402-559-3870
- Fax: 1-402-559-6018
- E-mail: editor-us@cancerbiomed.org
Editorial Board
Editor-in-Chief
Xi-Shan Hao, Tianjin Medical University Cancer Institute and Hospital, China
Executive Editor-in-Chief
Ning Zhang, Tianjin Medical University, China
Consultant
Run-Xian Bao, Tianjin Medical University Cancer Institute and Hospital, China
Webster Cavenee, University of California, USA
Bao-Cun Sun, Tianjin Medical University Cancer Institute and Hospital, China
Zhao-You Tang, Fudan University, China
Associate Editor-in-Chief
Xiu-Wu Bian, Southwest Hospital, China
Kai Fu, University of Nebraska Medical Center, USA
Mary Gospodarowicz, University of Toronto, Canada
Raphael E. Pollock, The Ohio State University, USA
Er-Wei Song, Sun Yat-sen University, China
Cheng-Chao Shou, Beijing Cancer Hospital, China
Yun-Hua Yang, Tianjin 4th Center Hospital, China
Qi-Min Zhan, Cancer Hospital Chinese Academy of Medical Sciences, China
Wei Zheng, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, USA
Peng-Bo Zhou, Weill Cornell Medical College, USA
Managing Editor
Hui-Qin Liu, Tianjin Medical University Cancer Institute and Hospital, China
Editor
Wen Li, Tianjin Medical University Cancer Institute and Hospital, China
Ying Li, Tianjin Medical University Cancer Institute and Hospital, China
Editorial Board Member
Mari Mino-Kenudson, Massachusetts General Hospital & Harvard Medical School, United States
David C. Madoff, Weill Cornell Medicine, USA
Aziz Nazha, Cleveland Clinic, Taussig Cancer Institute, USA
Luca Saragoni, G.B. Morgagni-L. Pierantoni Hospital, Italy
Alex Matter , A*STAR, Singapore
Thomas A. Sellers, Moffitt Cancer Center, USA
Nehmat Houssami, The University of Sydney, Australia
Fatima Cardoso, Champalimaud Clinical Centre, Portugal
Lim Soon Thye, National Cancer Centre Singapore, Singapore
Chantragan Srisomsap, Chulabhorn Research Institute, Thailand
John R. Adler Jr, Stanford University School of Medicine， USA
Riccardo Audisio, University of Liverpool, UK
Yi Ba, Tianjin Medical University Cancer Institute and Hospital, China
Vivian Barak, Hadassah-Hebrew University Medical Center, Israel
Robert C. Bast, Jr, University of Texas MD Anderson Cancer Centre, USA
Francesco Bertoni, IOR Institute of oncology research, Switzerland
Jean Yves Blay, Centre Léon-Bérard, France
Franco Cavalli, Oncology Institute of Southern Switzerland, Switzerland
Eduardo Cazap, Latin American and Caribbean Society of Medical Oncology, Argentina
Wing C. Chan, University of Nebraska Medical Center, USA
Wing-Cheong Chow, Hong Kong Baptist University, China
Charles S. Cleeland, The University of Texas MD Anderson Cancer Center, USA
Mario Dicato, Luxembourg Medical Center, Luxembourg
Julie Y. Djeu, Moffitt Cancer Center, USA
Jia Fan, Fudan University, China
Ardeshir Gravamzadeh, Haematology Oncology & BMT, Iran
Nagy A. Habib, Imperial College, Hammersmith Hospital Campus, UK.
Marc-Eric Halatsch, University of Ulm, Germany
Stanley R. Hamilton, The University of Texas MD Anderson Cancer Center, USA
Ji-Hui Hao, Tianjin Medical University Cancer Institute and Hospital, China
Jörgen Larsson, Lund University, Sweden
Soo-Yong Lee, Korea Cancer Center Hospital, Korea
Xiang-Huo He, Shanghai Jiao Tong University, China
Michael Koutsilieris, Medical School of the University of Athens, Greece
Gregory N. Fuller, The University of Texas MD Anderson Cancer Center, USA
Wen-Qi Jiang, Sun Yat-sen University Cancer Center, China
Irene M. Leigh, University of Dundee, UK
Daehee Kang, Seoul National University, Korea
Tezer Kutluk, Hacettepe University Faculty of Medicine, Turkey
David J. Hill, Cancer Council Victoria, Australia
Yang-Long Hou, Peking University, China
Kelly K. Hunt, The University of Texas MD Anderson Cancer Center, USA
Bing-Hui Li, Tianjin Medical University Cancer Institute and hospital, China
Jin Li, Fudan University, China
Li Li, Guangxi Medical University, China
Qiang Li, The Second Hospital of Tianjin Medical University, China
Wen-Bin Li, Beijing Shijitan Hospital, China
Yan Li, Zhongnan Hospital of Wuhan University, China
Niki Karachaliou, USP Instituto Universitario Dexeus, Spain
Dong-Xin Lin, Cancer Hospital Chinese Academy of Medical Sciences, China
Pei-Fang Liu, Tianjin Medical University Cancer Institute and Hospital, China
Bo Lu, Thomas Jefferson University, USA
Min Lu, Capital Medical University, China
Heinz Zwierzina, Medizinische Universität Innsbruck, Austria
Christoph Zielinski, Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria
Zong-Jian Zhu, Colorado State University, USA
Fang Yan, Vanderbilt University, USA
Paul Workman, Institute of Cancer Research, UK
Xi Wang, Dana-Farber Cancer Institute, USA
Julie M. Vose, University of Nebraska Medical Center, USA
Kari J. Syrjänen, Biohit HealthCare Oyj, Finland
Aru W. Sudoyo, Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Indonesia.
Daniel Sullivan, Moffitt Cancer Center, USA
Robert Z. Qi, The Hong Kong University of Science and Technology, Hong Kong, China
Purvish M. Parikh, Indian Cancer Society, India
Qiang Liu, Sun Yat-sen University, China
Ya-Ping Liu, Cancer Council NSW, Australia
Zhe Liu, Tianjin Medical University, China
Zhi-Hua Liu, Cancer Hospital Chinese Academy of Medical Sciences, China
W. Jack Pledger, Moffitt Cancer Center, USA
Sibrand Poppema, University of Groningen, University Medical Center Groningen, Netherlands
Lun-Xiu Qin, Fudan University, China
Xiu-Bao Ren, Tianjin Medical University Cancer Institute and Hospital, China
Chang Hun Rhee, Korea Cancer Center Hospital, Korea Institute of Radiation and Medical Sciences, Korea
Frank Romeo, Temple University Philadelphia, USA
Nathaniel Rothman, National Cancer Institute, USA
Zong-Hong Shao, Tianjin Medical University General Hospital, China
Kazuo Tajima, Mie University Graduate School of Medicine, Japan
Gary M. K. TSE, The Chinese University of Hong Kong, China
Hua-Qing Wang, Tianjin Union Medicine Centre, China
Jie Wang, Beijing Cancer Hospital & Beijing Institute for Cancer Research, China
Lu-Hua Wang, University of Texas MD Anderson Cancer Centre, USA
Qin-Hong Wang, Fudan University, China
Ying Wang, Tianjin Medical University Cancer Institute and Hospital, China
Fu-Chan Wei, Chang Gung University, Taipei, China
Dennis Weisenburger, City of Hope National Medical Center, USA
Qiao Wu, Xiamen University, China
Rui-Hua Xu, Sun Yat-sen University Cancer Center, China
Xiang-Liang Yang, Huazhong University of Science & Technology, China
Hai-Fang Yin, Tianjin Medical University, China
Guo-Guang Ying, Tianjin Medical University Cancer Institute and Hospital, China
Herbert Yu, Yale School of Public Health, USA
Shi-Ying Yu, Huazhong University of Science & Technology, China
Shun-Jiang Yu, Beijing Shijitan Hospiatal, China
Yuan Yuan, The First Hospital of China Medical University, China
Rong-Xin Zhang, Tianjin Medical University, China
Jian-Feng Zhou, Huazhong University of Science & Technology, China
|
